TABLE 3.

Prevention of toxoplasmosis and PCR follow-up practices for transplantation patients (15 centers)

Type of transplantation center, PCR follow-up, or prevention practice	Result for transplantation patient group
Type of transplant [total (mean ± SEM) no. of patients]
Solid organ transplantation (2009–2011)
Kidney (14 centers)	3,711 (265 ± 97)
Heart (10 centers)	549 (50 ± 32)
Liver (12 centers)	2,262 (174 ± 86)
Hematopoietic stem cell transplantation (2009–2011)
Allograft (13 centers)	2,463 (189 ± 79)
Autograft (14 centers)	3,318 (237 ± 101)
PCR follow-up [no. of centers with characteristic/total no. of centers (%)]
Systematic PCR follow-up
Allograft patients	8/13 (61)
Heart transplant patients	1/10 (10)
Frequency of blood PCR follow-up in allo-HSCT patients
2×/wk	1/8 (12.5)
1×/wk	4/8 (50)
2×/mo	2/8 (25)
1×/mo	1/8 (12.5)
Chemoprophylaxis [no. of centers using it/total no. of centers (%)]
Kidney transplanta	14/14 (100)
Heart transplantb	10/10 (100)
Liver transplantc	5/12 (42)
Allograft transplantd	11/13 (85)
Autograft transplante	1/14 (7)

^aDuration of chemoprophylaxis was variable across centers: 4 to 6 weeks (2 centers), 3 months (4 centers), 6 months (7 centers), unknown (1 center).

^bDuration of chemoprophylaxis was variable across centers: 4 to 6 weeks (1 center), 3 months (1 center), 6 months (6 centers), 1 year (1 center), lifelong if mismatch (1 center).

^cDuration of chemoprophylaxis was variable across centers: 6 months (3 centers), variable (1 center), lifelong (1 center).

^dDuration of chemoprophylaxis was variable across centers: 6 months (4 centers), guided by CD4⁺ T cell count (4 centers), 1 year (3 centers).

^eDuration of 3 months.